Fundraising Fox新元素药业
1 known investors
Find your way into 新元素药业
Sign up to see every warm intro you have to 新元素药业
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 新元素药业 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Atom Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for chronic gout, acute gout, and hyperuricemia. Its lead candidate ABP-671 is in multicenter Phase 2b/3 trials worldwide, including the US.
Investors · 1
Frequently asked questions
- What does 新元素药业 do?
- Atom Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for chronic gout, acute gout, and hyperuricemia. Its lead candidate ABP-671 is in multicenter Phase 2b/3 trials worldwide, including the US.
- Who are 新元素药业's investors?
- 新元素药业's investors include EFung Capital.